Rationale Cocaine use disorder (CUD) remains difficult to treat with no FDA-approved medications to reduce relapse. Antagonism of metabotropic glutamate receptor 5 (mGlu5) has been demonstrated to decrease cocaine-seeking but may also further compromise cognitive function in long-term cocaine users. Objectives Here we assessed the effect of repeated administration of negative or positive allosteric modulators (NAM or PAM) of mGlu5 on both cognitive performance and (context+cue)-primed cocaine-seeking after prolonged abstinence (≥ 45 days). Methods Adult male Sprague-Dawley rats underwent 6 days of short-access (1 h/day) and 12 days of long-access (6 h/day) cocaine self-administration. Rats were then trained and tested in a delayed match-to-sample (DMS) task to establish baseline working memory performance over a 5-day block of testing. Next, rats received daily systemic administration of the mGlu5 NAM 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine hydrochloride (MTEP; 3 mg/kg), the mGlu5 PAM 3-cyano-N-(1,3diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB; 30 mg/kg) or vehicle prior to DMS testing during a block of 5 days, followed by a 5-day washout DMS testing block. Results MTEP and CDPPB decreased drug-seeking in response to cocaine-associated cues after prolonged abstinence. However, repeated treatment with MTEP impaired working memory, while CDPPB had no effects on performance. Conclusions These results emphasize the relevance of evaluating cognitive function within the context of investigating pharmacotherapies to treat CUD. Further research is needed to determine how two mechanistically different pharmacological compounds can exert the same behavioral effects to reduce cocaine-seeking.
Introduction
Cocaine use disorder (CUD) is a chronic condition characterized by an inability to limit drug intake despite negative consequences (Koob and Volkow 2016) . Currently, no available FDA-approved medications possess the safety profile or display clinical efficacy to reduce relapse rates in CUD. A challenge to treat CUD has been partially attributed to elevated cocaine craving (Gawin and Kleber 1986) and increased reactivity to cocaine-associated cues (Parvaz et al. 2016 ) that persists over extended periods of abstinence, a phenomenon also replicated in animals (Grimm et al. 2001) . A number of neuroadaptations that may be responsible for elevated cocaine-seeking after a drug-free period have been identified in animal studies. One of the best-characterized and replicated findings is that of glutamate release into the nucleus accumbens (NAc) during the reinstatement of drug-seeking in rats (for review, see Scofield et al. 2016) . Though dysregulated glutamate homeostasis at corticostriatal synapses is thought to be primarily responsible (McFarland et al. 2003) , other glutamatergic inputs (such as those from the hippocampus, basolateral amygdala, and mediodorsal thalamus) may also contribute to the elevated glutamate release during cocaine craving and relapse (Matzeu et al. 2015; Pelloux et al. 2018; Rogers and See 2007) . Thus, it has been proposed that Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00213-019-05351-8) contains supplementary material, which is available to authorized users. pharmacotherapies that limit excessive glutamate release or reduce postsynaptic glutamate binding may promote abstinence (Uys and LaLumiere 2008) . Due to potentially severe adverse side effects of ionotropic glutamate receptor antagonists, pharmacological modulation of postsynaptic metabotropic glutamate receptor 5 (mGlu5) has been explored as a viable approach for the development of anti-relapse therapies (Olive 2009) . A large number of preclinical studies demonstrate that systemic and intra-accumbens administration of mGlu5 antagonists or negative allosteric modulators (NAMs) selectively limit cocaine reward and reduce cocaine-seeking, broadening the appeal of mGlu5 inhibitors as therapeutics for CUD (Chiamulera et al. 2001; Keck et al. 2013 Keck et al. , 2014 Kenny et al. 2005; Knackstedt et al. 2014; Knackstedt and Schwendt 2016; Kumaresan et al. 2009; Lee et al. 2005; Li et al. 2018; Martin-Fardon et al. 2009; Wang et al. 2013) .
Despite this evidence advocating for the use of mGlu5 inhibitors in anti-relapse therapy, there are potential complications that may prevent clinical use of these compounds. As mGlu5 receptors play a central role in certain forms of synaptic plasticity (such as long-term depression), it is not surprising that brain-wide inhibition or ablation of mGlu5 can produce learning and memory side effects (for review, see Simonyi et al. 2005; Olive 2010 ). When considering novel approaches to treatment of CUD, it is critical to evaluate and consider potential cognitive side effects, since up to 30% of dependent cocaine users and 12% of recreational users already exhibit global neurocognitive impairment (Vonmoos et al. 2013) . Specifically, deficits spanning multiple domains such as attention, working memory, and executive function have been documented in subjects diagnosed with CUD (Cunha et al., 2013; Goldstein et al., 2004; Jovanovski et al., 2005; Kübler, Murphy, & Garavan, 2005; Pace-Schott et al., 2008; Potvin et al., 2014; Vonmoos et al., 2013 Vonmoos et al., , 2014 . Moreover, cognitive deficits may compromise overall treatment outcomes in CUD, as their severity correlates with increased craving (Vonmoos et al. 2013 ) and relapse susceptibility (Verdejo-Garcia et al. 2014) , reduced impulse control (Albein-Urios et al., 2012) , or decreased efficacy of cognitive-behavioral therapy (Aharonovich et al. 2006; Streeter et al. 2008) . In recent years, several known cognitive enhancers were evaluated as potential treatments for substance use disorders (for review, see Brady et al., 2011; Mahoney, 2018) . However, these studies revealed no, or only modest, benefit of cognitive enhancers on cocaine use or abstinence rates (Dackis et al., 2005; Morgan et al., 2016; Nuijten et al., 2015) , and did not concurrently investigate efficacy of these compounds on both cognitive function and cocaine relapse.
This study aimed to address this knowledge gap by evaluating the effects of mGlu5 NAMs and PAMs in an animal model of CUD that allows for the within-subject evaluation of cocaine-seeking and cognitive performance. To that end, we assessed cocaine-seeking in rats with a history of extended (long) access cocaine self-administration after a period of prolonged abstinence (≥ 45 days) that corresponded with a time point during which "incubation of cocaine craving," or elevated ("incubated") responses to cocaine-associated cues have been previously demonstrated in both humans (Parvaz et al. 2016 ) and rodent models (Freeman et al., 2008; Grimm et al. 2001; Lu et al., 2003) . During this period, the effects of repeated treatment with mGlu5 allosteric modulators on working memory performance and cocaine-seeking were evaluated in the delayed match-to-sample (DMS) task and upon reexposure to cocaine paired context and cues (relapse test). Using this experimental design, we have recently reported that extended-access cocaine self-administration produces not only robust cocaine-seeking but also persistent working memory deficits that are related to long-term changes in metabolic activity and mGlu5 expression within the prefrontal cortex (Gobin et al. 2019 ). Here, we tested the following hypotheses:
(1) chronic systemic administration of an mGlu5 NAM will impair working memory; (2) chronic systemic treatment with an mGlu5 PAM will improve working memory; and (3) acute administration of the mGlu5 NAM, but not PAM, will attenuate cocaine-seeking. We chose to evaluate the mGlu5 NAM 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine hydrochloride (MTEP) and the mGlu5 PAM 3-cyano-N-(1,3-diphenyl-1Hpyrazol-5-yl)benzamide (CDPPB), due to their low toxicity as well as the wealth of scientific data supporting anti-relapse properties of MTEP (Keck et al., 2014; Knackstedt and Schwendt 2016; Knackstedt et al. 2014, b; Kumaresan et al. 2009 ) and pro-cognitive properties of CDPPB (Uslaner et al. 2009; Stefani and Moghaddam 2010; Reichel et al. 2011; Fowler et al. 2013; LaCrosse et al. 2014; Marszalek-Grabska et al. 2018 ).
Materials and methods

Subjects
Adult male Sprague-Dawley rats (Charles River Laboratories; 275 g on arrival; N = 38) were first acclimated to the animal facility for 1 week prior to any manipulation. They were housed individually, maintained on a 12-h reverse light/dark cycle (lights off at 0700), and given ad libitum access to food and water, except as noted below. All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Florida and were performed in accordance with the Guide for the Care and Use of Laboratory Animals. A timeline of the overall experimental design is depicted in Fig. 1 with individual behavioral procedures described below. Ten rats were excluded prior to assignment to receive drug or vehicle. Four of these rats died during the cocaine self-administration phase of the experiment, and six failed to reach the predetermined criterion during DMS training. Additionally, one rat was considered an outlier during the relapse test according to a Grubb's test for outliers and was thus excluded from the relapse dataset.
Drugs
Cocaine hydrochloride was acquired from the NIDA Controlled Substances Program (Research Triangle Institute, NC) and was dissolved in 0.9% sterile physiological saline. MTEP (Abcam Biochemicals, Cambridge, MA) and CDPPB (EAG Laboratories, Maryland Heights, MO) were dissolved in 10% Tween 80 (Sigma-Aldrich) in 0.9% NaCl. Tween 80 (10%) in 0.9% NaCl was used as the vehicle solution. MTEP was neutralized to pH 7.2-7.4 with 1 N NaOH. MTEP (3 mg/kg) was administered intraperitoneally (IP) 10 min prior to behavioral testing. The dose, timing, and route of MTEP administration were carefully selected based on previous reports. Specifically, this dose of MTEP resulted in a rapid and full receptor occupancy in adult Sprague-Dawley rats that is maintained for at least 1 h (Anderson et al. 2003) ; reduced cocaine-seeking (Martin-Fardon et al. 2009; Hao et al. 2010; Martin-Fardon and Weiss 2012) ; and was devoid of nonspecific effects on appetitive reinforcement or motor function Martin-Fardon et al. 2009 ). CDPPB was administered subcutaneously (SC) at a dose of 30 mg/kg, 20 min prior to behavioral testing based on previously published evidence showing pro-cognitive effects of this dose on different types of learning (Stefani and Moghaddam 2010; Olive 2010; Reichel et al. 2011; Fowler et al. 2013 ) without locomotor side effects ).
Surgery and cocaine self-administration
All rats were implanted with jugular catheters and submitted to cocaine self-administration (SA) as previously described (Gobin and Schwendt 2017; Gobin et al. 2019) . Rats were anesthetized with ketamine (87.5 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.), and the jugular vein was implanted with Silastic tubing (Dow Corning, Midland, MI). Rats were treated with ketorolac (3 mg/kg, i.p.) to provide analgesia for the first three days of a 5-day recovery period. Catheters were flushed daily with 0.1 ml of 100 U/ml of heparinized saline and catheter patency was periodically tested by intravenous administration of methohexital sodium (10 mg/ml).
Beginning during cocaine SA and lasting throughout the duration of the experiment, rats were restricted to 15-20 g of food per day to maintain~85% of free-feeding weight (Gobin and Schwendt 2017; Gobin et al. 2019) .
Rats underwent SA procedures using modified rat operant chambers (30 × 24 × 30 cm; Med Associates, St. Albans, VT) equipped with two standard rat nose poke ports. The chambers were modified to include a mesh wire floor, striped wall pattern, and vanilla scent in order to provide a context that was distinct from the one used in the operant cognitive tasks as described below. Nose poking in the active port resulted in delivery of cocaine (0.35 mg/100 μl infusions) on a FR1 schedule of reinforcement. A 5-s presentation of a light + tone cue was paired with each infusion followed by a 20-s "timeout" period in which nose poking was recorded but not reinforced. Nose poking in the inactive port was recorded but did not result in drug or cues. Rats underwent daily 1-h (short access, ShA) sessions for 6 days, followed by daily 6-h (long access, LgA) sessions for 12 days. Next, rats entered a prolonged abstinence period during which they began training in the operant DMS task 3 days following the last day of SA.
Operant delayed match-to-sample task
Rats were trained and tested in the DMS task as previously described (Sloan et al. 2006; Beas et al. 2013; Gobin et al. 2019) . Daily 40-min sessions were conducted in standard rat operant chambers (30 × 24 × 30 cm; Med Associates, St. Albans, VT) equipped with two levers. Within each session, individual trials were composed of three phases-a sample phase, a delay period, and a choice phase. During the sample phase, the presentation of the left or right lever was randomly selected by the program such that each lever was presented approximately the same number of times throughout each session. Upon a lever press, the lever was retracted, one sucrose pellet was delivered, and the delay interval was initiated with randomized delay durations. During the choice phase, both levers were extended, and pressing the same lever presented in the sample phase was scored as a correct response and resulted in delivery of one sucrose pellet. Pressing the incorrect lever resulted in a 6-s time-out period wherein no sucrose pellet was delivered, the house light was extinguished, and both levers were retracted. Rats were initially trained without any delays between the sample and choice phase. A correction procedure was employed to prevent the daily prior to DMS testing, for a block of five consecutive days. This was followed by another 5-day block of DMS testing, during which no drugs were administered ("Washout"). One group of rats (1 × CDPPB group; n = 7) did not receive any drug treatments; instead, after they completed the baseline DMS testing, they proceeded directly to relapse testing as described below. See the experimental timeline ( Fig. 1) for details.
Relapse tests
On the day after the final day of DMS testing, all rats underwent a 45-min context+cue relapse test in the SA chamber, wherein the cues previously paired with cocaine were presented upon nose poking in the previously active port without cocaine delivery. Rats who received drug treatments prior to DMS testing were administered the same compounds prior to the relapse test. A second context+cue relapse test without prior drug treatments was conducted the following day to assess washout drug effects. Additionally, to assess the effect of a single administration of CDPPB on "relapse" without previous repeated treatment with the compound, one group of rats (n = 7) underwent two 5-day blocks of DMS testing (during which no drug was administered) and only received a single injection of CDPPB 20 min prior to the relapse test ( Fig. 1) . A group receiving a single injection of MTEP was not included since it has been previously demonstrated that a single systemic administration of MTEP reduces cocaine relapse (Knackstedt and Schwendt 2016) . Since rats reached the criterion and finished testing in the DMS test at different time points, the range for the day of relapse testing was 45-80 days. It is unlikely this factor significantly influenced our data, as responding to drug-associated cues remains high, but stable between 30 and 100 days of post-cocaine abstinence (Freeman et al. 2008 ).
Locomotor testing
The effects of drug treatment on spontaneous noveltyinduced locomotion were tested in a standard open-field chamber (40 × 44 × 37 cm) equipped with photobeam activity sensors (San Diego Instruments). Locomotor activity was measured as number of beam breaks recorded over a 1-h test session. Drug administration parameters, as well as the treatment group assignments, were carried over from DMS and relapse testing.
Statistical analysis
IBM SPSS (Version 25) and GraphPad Prism (Version 5.03) software were used to analyze data. The alpha level was set at 0.05 for all statistical analyses used. A repeated-measures ANOVA was used to analyze discrimination between the active and inactive nose poke ports across the 18 daily sessions of cocaine SA, with Port as the between-subjects factor and Day as the within-subjects factor. To assess cocaine escalation, a repeated-measures ANOVA was conducted to compare mean cocaine intake across the 12 daily LgA sessions of cocaine SA. DMS task acquisition was calculated as the total number of days to meet criterion prior to entering the DMS testing phase. A one-way ANOVA was conducted to assess group differences in number of days to reach criterion prior to DMS testing. During the DMS testing phase, "percent correct" was the primary dependent measure. Percent correct at each delay interval {0 s, 2 s, 4 s, 8 s, 12 s, 18 s, 24 s} was averaged over each 5-day testing block. A repeated-measures ANOVA was used to assess the effect of treatment on working memory performance for each condition with Block (Baseline, Drug, Washout) as the between-subjects factor and Delay as the within-subject factors. During the relapse tests, our measure of cocaine-seeking was operationalized as the number of responses in the previously active port compared with the inactive port. A two-way ANOVA was used to assess group differences in the number of nose pokes in the active and inactive ports during both context+cue relapse test days. A one-way ANOVA was conducted to assess group differences in locomotor performance. Bonferroni post hoc tests were used when appropriate.
Results
Rats escalated cocaine intake during long-access cocaine self-administration
All rats demonstrated successful discrimination between the active and inactive nose poke port throughout SA ( Fig. 2a) Greenhouse-Geisser correction showed that rats displayed an escalation of cocaine intake (mg/kg) over the 12 days of LgA sessions (F(5.20, 171.68) = 15.69, p < 0.001). Post hoc tests using Bonferroni correction revealed that cocaine intake on LgA days 4-12 was significantly higher than on day 1 (p < 0.05; Fig. 2b ). On average, total cocaine intake (± SEM) for the whole period of self-administration was 821.05 ± 32.86 mg/kg, with the long-access self-administration phase accounting for the majority of cocaine intake, 778.04 ± 29.75 mg/kg.
Rats did not differ in DMS task acquisition or baseline performance prior to treatment A one-way ANOVA did not reveal a difference between groups on task acquisition prior to treatment (F(3, 25) = 1.35, n.s.; Fig. 3a ). Prior to behavioral pharmacology testing, rats were matched to treatment groups such that there were no group differences in total cocaine intake (F(3, 25) = 2.76, n.s.) and baseline DMS performance across all delays (no effect of group F(3, 25) = 1.58, n.s.; and no interaction F(18, 144) = 1.21, n.s). Fig. 3 Delayed match-to-sample task (DMS). a Animals assigned to four treatment groups did not display pre-existing differences in task acquisition (number of days to reach criterion). p < 0.001) were found without a significant Delay × Block interaction (Fig. 3b ). For the MTEP treatment group, main effects of Delay (F(6, 84) = 51.52, p < 0.0001) and Block (F(2, 84) = 26.99, p < 0.0001) as well as a Delay × Block interaction (F(12, 84) = 3.05, p < 0.01) were found (Fig. 3c) . Bonferroni post-tests revealed that MTEP treatment reduced the percent correct at the 12-s, 18-s, and 24-s delays compared with baseline (ps < 0.01-0.001). MTEP performance was also impaired at 8 s, 12 s, 18 s, and 24 s compared with the washout block (ps < 0.001-0.05). (Fig. 3c ). For the CDPPB treatment group, main effects of Delay (F(6, 70) = 50.43, p < 0.0001) and Block (F(2, 70) = 9.06, p < 0.001) were found without a significant Delay × Block interaction (Fig. 3d) . The effects of MTEP on working memory are not likely due to decreased appetitive behavior, as groups did not differ in total number of trials completed averaged over the 5-day treatment block (F(2, 20) = 3.04, n.s). The mean (± SEM) number of trials completed over the 5-day treatment period was 103 ± 5.97 (Vehicle group), 101.7 ± 3.55 (MTEP group), and 116.5 ± 1.12 (CDPPB group).
MTEP impaired while CDPPB had neutral effects on working memory performance
Administration of either MTEP or CDPPB decreased drug-seeking in a context+cue relapse test
A two-way ANOVA revealed main effects of Port (F(1, 46) = 37.59, p < 0.0001), Treatment (F(3, 46) = 4.14, p < 0.05) and a Port × Treatment interaction (F(3, 46) = 3.46, p < 0.05) during the first relapse test (Relapse test+drug; Fig. 4a ). Bonferroni post hoc tests showed that rats in the MTEP, repeated CDPPB, and 1 × CDPPB groups exhibited less nose pokes in the previously active port compared with the Vehicle treatment group (ps < 0.01-0.001). Only rats in the Vehicle group significantly differed in the average number of nose pokes in the active port vs. the inactive port (p < 0.001). On the following day (Day 2 relapse test without drug treatment), a two-way ANOVA revealed a main effect of Port (F(1, 46) = 45.98, p < 0.0001), but no effect of Treatment (F(3, 46) = 0.99, n.s) and no significant Port × Treatment interaction (F(3, 46) = 1.24, n.s). While not commonly done, under these circumstances, multiple comparisons among the treatment groups could be conducted (see Wei et al. 2012 ). Here we used this additional analysis to explore possible residual effects of prior drug treatment on Day 2 nose poke responding. While we did not find an effect of prior treatment on Day 2 active nose port responding (e.g., Vehicle vs. MTEP, p = 0.08), Bonferroni post hoc tests revealed a difference between active and inactive nose port responses within the Vehicle (p < 0.001), MTEP (p < 0.01), and 1 × CDPPB (p < 0.01) groups.
Neither drug treatment altered spontaneous novelty-induced locomotion
We evaluated whether the doses of the drugs used in this study affected locomotor activity. A one-way ANOVA showed that treatment groups (Vehicle, MTEP, CDPPB) did not differ in the overall locomotion in a novel environment, measured as average number of beam breaks during a 1 h test session (F(2, 19) = 1.74, n.s.). Mean number of beam breaks (± SEM) for each group was as follows: Vehicle (5023 ± 385.1), MTEP (4370 ± 229.3) and CDPPB (5529 ± 387.2). Also see the Supplementary Figure 1 .
Retesting of rats revealed possible delayed effects of CDPPB on DMS performance
After completion of the behavioral testing (~6 days after the Washout testing block) a subgroup of rats was re-introduced to the DMS task and tested for a period of 5 consecutive days (Retest block). Two-way ANOVAs were conducted to compare the most recent testing block (Washout) with the Retest block. For the group previously treated with Vehicle, only a main effect of Delay (F(6, 21) = 9.80, p < 0.0001) was found but no main effect of Block (F(1, 21) = 0.10, n.s.) and no significant interaction (F(6, 21) = 1.61, n.s.). Fig. 4 Relapse to cocaine-seeking. a Rats with a history of vehicle prior to DMS testing and relapse exhibited greater # nose pokes in the active port compared with rats with a history of MTEP (3 mg/kg, i.p.) and CDPPB (30 mg/kg, i.p.) prior to DMS testing and relapse as well as compared with rats given only a single administration of CDPPB prior to relapse. Vehicle-treated rats also nose poked more in the active nose port compared with the inactive nose port. b Groups did not differ on the # nose pokes in the previously active port on day 2. ***p < 0.001 vs. Veh active port nose pokes. ### p < 0.001 vs. inactive port nose pokes within each group. n = 5-8/group previously treated with MTEP, only a main effect of Delay (F(6, 7) = 191.8, p < 0.0001) was found, but no main effect of Block (F(1, 7) = 0.20, n.s.) and no significant interaction (F(6, 7) = 2.52, n.s.). For the group that previously received CDPPB, main effects of Delay (F(6, 35) = 25.90, p < 0.0001) and Block (F(1, 35) = 13.48, p < 0.001) were found, as well as a significant interaction (F(6, 35) = 6.22, p < 0.001). Post hoc tests using Bonferroni correction revealed improved working memory performance at the 24 s delay (p < 0.05) in rats previously treated with CDPPB, when compared with their most recent (Washout) testing block (Suppl. Fig. 2 ).
Discussion
Our data indicate that both allosteric inhibition and activation of mGlu5 reduces relapse to cocaine-seeking in rats, even after prolonged abstinence. At the same time, the dose of MTEP that decreased relapse also produced significant working memory deficits. On the other hand, allosteric activation of mGlu5 with CDPPB at a dose that reduced relapse, spared working memory, indicating that mGlu5 PAMs might offer a safer approach to reduce cocaine relapse. Expanding on previous studies showing that systemic MTEP reduces cocaine-seeking (Keck et al. 2014; Knackstedt and Schwendt 2016; Kumaresan et al. 2009 ), we are the first to report that systemic MTEP administration also attenuates (context+cue)-elicited cocaine-seeking following extended-access cocaine SA and prolonged abstinence (45-80 days). In other words, MTEP attenuates cocaine-seeking in animals that typically show sustained elevation of drugseeking and resistance to extinction, behavior previously described as "incubation of cocaine craving" (Grimm et al. 2001; Lu et al. 2003; Freeman et al. 2008) . We hypothesize that systemic MTEP is partially targeting the NAc to control drug-seeking as previous studies report that MTEP microinfused into the NAc is sufficient to reproduce the effects of systemic MTEP administration (Knackstedt et al. 2014, b; Li et al., 2018; Wang et al., 2013) . However, mGlu5 receptors are widely distributed in other brain regions (Rodrigues et al., 2002; Romano et al., 1995; Shigemoto et al., 1993) known to play a role in cue-elicited cocaine-seeking (Carelli et al. 2003; Pelloux et al. 2018) . As previous studies have shown that intraventromedial PFC or intra-dorsolateral STR blockade of mGlu5 do not reduce relapse to cocaine-seeking (Ben-Shahar et al., 2013; Knackstedt et al. 2014, b) , anatomically separate populations of mGlu5 in the brain may play distinct roles in regulating drug-seeking. Thus, possible contribution of mGlu5 receptors outside of the NAc to drug-seeking behavior warrants further, more comprehensive evaluation.
The MTEP-induced disruption of post-cocaine working memory performance was most apparent during longer delays (8-24 s), suggesting a delay-dependent (or load-dependent) impairment. These effects of MTEP were acute and did not persist past the drug treatment period (denoted here as washout). We recently found that the same regimen of cocaine selfadministration used in the present study produced deficits in working memory performance that persisted over weeks of drug-free abstinence (Gobin et al. 2019) . As all rats used in the current study had a cocaine history, their working memory ability was likely already impaired prior to MTEP administration, indicating that treatment with this class of drugs may produce further cognitive impairment in recovering addicts. The deficits produced by MTEP here are of comparable magnitude with those resulting from mPFC lesion in the same task (Sloan et al. 2006) . In addition to the mPFC, lesion and inactivation studies using match-to-sample and nonmatch-tosample operant tasks have identified that circuitry supporting "normal" working memory performance also includes the dorsomedial STR (Akhlaghpour et al. 2016) . Thus, we hypothesize that systemic MTEP may be impairing working memory through inhibition of specific corticostriatal circuits. The acute effects of MTEP here also suggest that mGlu5 activity is critical for ongoing working memory performance. Within the mPFC, mGlu5 is predominantly expressed postsynaptically on neurons projecting to various striatal regions, including the NAc and dmSTR (Romano et al. 1995) . Indeed, administration of MTEP directly into the mPFC impairs working memory using the analogous DMS task (Hernandez et al. 2018) .
As MTEP impaired working memory, we predicted that a mGlu5 PAM would enhance working memory. Here, we tested the effects of CDPPB, an mGlu5 PAM shown in other tasks to exert pro-cognitive effects (Uslaner et al. 2009; Stefani and Moghaddam 2010; Reichel et al. 2011; LaCrosse et al. 2014) . Surprisingly, we did not detect an effect of CDPPB on postcocaine working memory performance in rats. Previously, the s a m e d o s e o f C D P P B ( 3 0 m g / k g ) i m p r o v e d methamphetamine-induced episodic memory deficits (Reichel et al. 2011) , as well as MK-801-induced deficits in cognitive flexibility (Stefani and Moghaddam 2010) and spatial learning (Fowler et al. 2013) . Several factors may account for the lack of CDPPB effects in our study. First, CDPPB effects were commonly observed in significantly impaired animals, with the discrimination or response accuracy near, or at chance (e.g., see Stefani and Moghaddam 2010; Reichel et al. 2011) . In contrast, we have shown that chronic cocaine produces sustained, but moderate cognitive impairment in rats (Gobin and Schwendt 2017; Gobin et al. 2019) . Under these circumstances the effects of CDPPB might have been obscured. Next, it is possible that a history of extended cocaine access disrupts glutamatergic and mGlu5 receptor function in the mPFC (specifically in the prelimbic cortex, PrL) in a way that reduces the efficacy mGlu5 PAMs (Ben-Shahar et al. 2012 , Gobin et al. 2019 . Finally, facilitatory effects of CDPPB in an unimpaired population were previously observed during training phases (Fowler et al. 2013) . Here, the continued performance in the DMS task did not require new learning; on the contrary, rats underwent extensive training prior to drug treatment and testing. In order to assess possible delayed effects of CDPPB on the recall of the DMS task rules, we conducted a continuation study (maintaining individual group designations) wherein rats' working memory performance was re-evaluated at a later time point (6 days after the end of the washout period). Under these conditions, we did observe a partial enhancement of working memory performance (above the values recorded during the washout block) in rats previously treated with CDPPB (Suppl. Fig. 2 ), but not in rats with a history of Vehicle or MTEP treatment. These preliminary findings motivate future studies to (a) investigate the effects of mGlu5 allosteric modulation on cognitive performance during initial task training and/or recall and (b) to evaluate the benefits of this treatment in cocaine animals relative to their uncompromised (drug-naïve) counterparts. The latter approach will allow to assess the magnitude of "cognitive recovery" produced by mGlu5 PAMs in cocaine-experienced subjects.
In contrast to the divergent effects MTEP and CDPPB on working memory, both drugs reduced cocaine-seeking triggered by cocaine-associated context and cues. The antirelapse effects of CDPPB were not due to cumulative effects of prior repeated treatment with this drug (5-day CDPPB treatment regimen during DMS testing), as single CDPPB administration (20 min prior to the relapse test) also reduced cocaine-seeking. As intra-NAc administration of orthosteric mGlu5 agonist CHPG has been shown to promote cocaineseeking or conditioned effects of cocaine (Wang et al. 2013; Benneyworth et al. 2019) , potent anti-relapse effects of CDPPB may seem surprising. However, the relapse test as conducted in the current study is analogous to an extinction session on day 1 in studies that demonstrated extinctionenhancing effects of CDPPB (Olive 2010; Cleva et al. 2011) . Importantly, on extinction day 1, these studies show a similar CDPPB-induced decrease in overall responding to drug cues (Cleva et al. 2011) . Thus, the CDPPB-induced reduction in drug-seeking may be attributed to acute enhancement of extinction learning occurring already within the first session.
Allosteric modulators typically regulate functional receptor activity specifically in brain areas where the endogenous agonist exerts its physiological effects (Stansley and Conn 2019) . Thus, it is possible that MTEP and CDPPB (two mechanistically different compounds) may be acting at opposing brain regions to modulate mGlu5 function related to the expression of distinct behaviors (decreased motivation to seek the drug vs. enhancement of extinction learning) that would result in the same outcome (decreased overall responding in the relapse test). MTEP may be decreasing the ability of drug-associated cues to drive PrL brain activation and behavior (Kumaresan et al. 2009; Martin-Fardon et al. 2009; Keck et al. 2014 ) via an mGlu5-mediated inhibition of neuronal excitability within this region (Timmer and Steketee 2012) or the NA core (Wang et al. 2013 ), but not infralimbic cortex (IL, (Ben-Shahar et al. 2013) ), whereas CDPPB may be facilitating within-session extinction learning via an mGlu5mediated activation within the IL (Ben-Shahar et al. 2013 ). Furthermore, the efficacy of these modulators in enhancing mGlu5 activity depends on the concentration of endogenous/ orthostatic agonist (extracellular glutamate) and on mGlu5 agonist-modulator cooperativity factor (Stansley and Conn 2019) . As such, region-specific dysregulation of mGlu5 signaling (Gobin et al. 2019) , mGlu5 function (Ben-Shahar et al. 2013) , and glutamate homeostasis (Knackstedt and Kalivas 2009) after chronic cocaine may further determine circuitspecific effects of systemic MTEP and CDPPB administration.
The current study also assessed cocaine-seeking 1 day after the initial relapse test (Relapse test +drug), to evaluate possible carryover effects of prior pharmacological manipulations on cocaine-seeking (Relapse test −drug). Here, we show that prior treatment with MTEP or CDPPB did not affect drugseeking in this subsequent test. This finding is in agreement with our previous observations that single intra-dSTR, but not systemic MTEP administration interferes with post-relapse extinction learning (Knackstedt et al. 2014; Knackstedt and Schwendt 2016) . It is possible that repeated MTEP administration is needed to decelerate extinction (Kim et al. 2014 ). In the case of CDPPB, we again predict that its repeated daily administration is necessary to produce extinction-enhancing effects (Olive 2010) . It should be noted that one study observed an effect of CDPPB or MTEP administration on cocaine-seeking during a subsequent "undrugged" extinction test (Perry et al. 2016) . However, in this study, either compound was administered prior to a CS+ extinction session that was separate from operant extinction. Another factor not addressed in the aforementioned studies is the resistance to extinction in rats with a history of extended access to cocaine (Grimm et al. 2001; Lu et al. 2003; Freeman et al. 2008) , and also observed in our Vehicle-treated rats. Thus, it is possible that longer extinction sessions (45 min vs. 2 h) are necessary to observe retarding or faciliatory effects of mGlu5 NAMs or PAMs on extinction in these animals.
Conclusions
The current study is the first to investigate the effects of positive and negative mGlu5 allosteric modulation on both cognitive performance and persistent cocaine-seeking. We found that repeated systemic administration of the mGlu5 NAM MTEP impaired working memory performance, while mGlu5 PAM CDPPB had no effect. Interestingly, both compounds attenuated relapse to cocaine-seeking triggered by combined discrete and contextual cocaine cues, without affecting subsequent extinction learning. We hypothesize that systemic administration of MTEP reduces the ability of mGlu5 receptors within the cortico-accumbal pathway to mediate cocaine-seeking, at the cost of inhibiting working memory processes. On the other hand, the ability of CDPPB to exert the same anti-relapse effect (though free of cognitive side effects) makes mGlu5 allosteric modulation an attractive target for the development of future therapies of CUD. These initial observations motivate further research into the brain circuitry and neurobiological mechanisms through which mGlu5 PAMs reduce drug-seeking.
